Citigroup Inc Achilles Therapeutics PLC Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.79 - $2.39 $18 - $57	24 Added 3.74%	666 $0
Q3 2022 Nov 10, 2022	SELL	$2.26 - $3.38 $27 - $40	-12 Reduced 1.83%	642 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.96 - $3.04 $372 - $577	-190 Reduced 22.51%	654 $2,000
Q1 2022 May 12, 2022	SELL	$2.8 - $5.23 $954 - $1,783	-341 Reduced 28.78%	844 $2,000
Q4 2021 Feb 10, 2022	BUY	$4.22 - $8.86 $5,000 - $10,499	1,185 New	1,185 $6,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.